This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
1 Citations 8 Q&As
Facts about Tumor necrosis factor ligand superfamily member 4.
.
Human | |
---|---|
Gene Name: | TNFSF4 |
Uniprot: | P23510 |
Entrez: | 7292 |
Belongs to: |
---|
tumor necrosis factor family |
CD134 ligand; CD134L; CD252 antigen; CD252; Glycoprotein Gp34; gp34; OX40 antigen ligand; OX40 Ligand; OX40L; OX-40L; OX4OL; TAX transcriptionally-activated glycoprotein 1; tax-transcriptionally activated glycoprotein 1 (34kD); tax-transcriptionally activated glycoprotein 1, 34kD; TNFSF4; tumor necrosis factor (ligand) superfamily, member 4; tumor necrosis factor ligand superfamily member 4; TXGP1
Mass (kDA):
21.05 kDA
Human | |
---|---|
Location: | 1q25.1 |
Sequence: | 1; NC_000001.11 (173183729..173462208, complement) |
Membrane; Single-pass type II membrane protein.
This article will discuss the PicoKine Human TNFSF4/OX40L ELISA kit PicoKine. This kit makes use of high-affinity primary antibodies to test for TNFSF4 in biological samples. It is available to researchers around the world. In addition, you'll learn how to utilize the PicoKine Human TNFSF4/OX40L ELISA Kit for clinical use.
The TNFSF4 Marker is an immunoglobulin that binds to human cytokeratins. It is available as liquid and can be stored at -20°C for up to a year. The price of blocking peptides varies on the length of the immunogen, which can range between $1 and $600 per grams. Scientists may submit results from their studies to Boster Bio for product credits.
The Human TNFSF4/OX40 ELISA Kit detects the concentration of TNFSF4/OX40L plasma, serum, and tissues homogenates. It is accurate and reproducible. This kit employs the sandwich ELISA technique, in which an antibody from a mouse that is specific for TNFSF4 is precoated onto an 96-well plate. The standards and test samples are then added to each well, and the biotinylated detect antibody is added after. The conjugates that are not bound are eliminated by using TBS buffer or PBS.
TNFSF4/OX40L belongs to the TNF superfamily. TNFSF4 encodes a protein with a mass is 21,050 daltons. It is the human gene responsible for TNFSF4. The human gene is linked to Lupus erythematosus. There are three variants of the ELISA kit for humans, mouse, and rat.
The DuoSet ELISA Development Kit contains all the necessary components to support sandwich ELISA development. The kit analyzes recombinant and natural human TNFSF4/OX40L levels in serum and plasma. The kit recommends a diluting solution that is compatible with the majority of supernates for cell culture. Complex matrices, for example, plasma or serum, should be assessed prior to use.
We first identified stem cells that were phenotyped as CD44+/24 to further investigate the potential role of TNFSF4 for immunotherapy against cancer. TNFSF4 is a cytokine which partially functions by neutralizing stem cells. Therefore, it is an important target for immunotherapy against cancer. We will explore the potential role of TNFSF4 in the development of breast cancer immunotherapies.
TNFSF4 is an element of the tumor necrosis factor superfamily of ligands and is associated with the genes CD252 and OX40L. It is expressed on DC2s (a subtype of dendritic cell) and is involved in the pathogenesis of many diseases. Human TNFSF4 shares 46% amino acids with its mouse counterpart. It is produced by a single-cell monooxygenase (Thomas's-P-L-Meliss-P-Fluoride-Serum-Mazet-Possud-Flux-CD34-OX40L-C-K-R-P-L-Melisia) cell line.
The expression of TNFSF4 is linked to tumor immune invasion. Other costimulatory proteins, like TNFSF9 or TNFSF18, have little association with CD4+ T cells infiltration. It is not clear what the TNFSF4 marker can be used for cancer immunotherapy. It could be useful for monitoring patients suffering from the TNFSF4 gene mutation. This research is vital in case you are concerned about the accuracy and reliability of the TNFSF4 genes.
A new study in mice found that TNFSF4 was an immunotherapeutic target. It is also associated with other genes, such as ALDh2A1 and KRAS and ALDh2A1, it also has a correlation with the p53, IL-2 and the mTOR. These findings suggest that TNFSF4 could be a useful diagnostic tool in cancer immunotherapy. For this reason, this marker has the potential to aid physicians in determining the most effective cancer immunotherapy approach for the patient's particular needs.
OX40L, also known as TNFSF4 is a member of the tumor necrosis factors superfamily. It interacts with OX40L and is expressed by activated T cells. In humans, OX40L increases expression of TNFSF4 and is involved in the regulation of the function of the effector cell. This antibody recognizes a subset of OX40L variants that may be linked to the development of systemic Lupus Erythematosus (SLE) syndrome which is a genetic condition that is possibly linked to TNFSF4 gene mutations.
These antibodies are made using an scFv-TNFSF format. SCFv is short for single-chain fragment variable, and TNFSF stands for tumor necrosis factor superfamily. In addition that the scFv comes with a VH/L variable region of the antibody heavy chain. The extracellular domain (ECD) of these antibodies is the one responsible for their ability to recognize TNFSF4.
The bifunctional antibody-fusion protein has been confirmed with flow cytometry and the TNFSFR recombinant. It was then tested in co-culture assays to determine the co-stimulatory power of these antibodies. The fused protein stimulated T cell proliferation and the production of IFNg during the tests. To confirm the efficacy of this antibody, further research is needed.
In addition to TNFSF4, scFv-TNFSF10B is another drug targeted at TNFSF4-positive tumors. Clinical trials have shown that scFvTNFSF10B has higher EC50 values than its predecessor, and superior PK properties. This makes it a potential possibility for molecule development. This antibody is extremely specific for cancer cells that express TNFSF4. lines.
Recent research has revealed that the TNFSF4 marker is linked to the lower risk of myocardial damage. Researchers also discovered a link between miR320b and CK. These are two other miRs that could play a role in the development of atherosclerosis. The results of this study suggest that miR-320b may be an additional diagnostic marker for AMI.
The study revealed 11,053 putative functional SNPs in 6,891 genes. After having reduced the number of hypotheses suggested, the researchers discovered variations in four genes linked with myocardial infarction risk such as (PALLD (palladin, cytoskeletal associated protein) and ROS1 (v-ros UR2-avian sarcoma virus oncogene homolog 1), TAS2R50 (taste receptor family 2 member 50), and OR13G1. Further research is required to determine the effectiveness of these polymorphisms to assess CHD risk or identifying novel targets.
Researchers also discovered that patients with high levels of hsCRP had a twice higher chance to develop CAD than patients with C-reactive proteins. This was due to the fact that hsCRP has been discovered to be the most accurate indicator of the likelihood of developing CAD. A high level of C-reactive protein (CRP) in men, was three times more likely an upcoming MI than those with low levels.
PMID: 1996093 by Miura S., et al. Molecular cloning and characterization of a novel glycoprotein, gp34, that is specifically induced by the human T-cell leukemia virus type I transactivator p40tax.
PMID: 7913952 by Godfrey W.R., et al. Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor.
*More publications can be found for each product on its corresponding product page